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Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. A single-nucleotide polymor-
phism (SNP), rs6834314, was associated with serum liver enzymes in the general population, presumably ref lecting 
liver fat or injury. We studied rs6834314 and its nearest gene, 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13), 
to identify associations with histological features of NAFLD and to characterize the functional role of HSD17B13 
in NAFLD pathogenesis. The minor allele of rs6834314 was significantly associated with increased steatosis but 
decreased inf lammation, ballooning, Mallory-Denk bodies, and liver enzyme levels in 768 adult Caucasians with 
biopsy-proven NAFLD and with cirrhosis in the general population. We found two plausible causative variants in 
the HSD17B13 gene. rs72613567, a splice-site SNP in high linkage with rs6834314 (r2 = 0.94) generates splice vari-
ants and shows a similar pattern of association with NAFLD histology. Its minor allele generates simultaneous 
expression of exon 6-skipping and G-nucleotide insertion variants. Another SNP, rs62305723 (encoding a P260S 
mutation), is significantly associated with decreased ballooning and inf lammation. Hepatic expression of HSD17B13 
is 5.9-fold higher (P = 0.003) in patients with NAFLD. HSD17B13 is targeted to lipid droplets, requiring the con-
served amino acid 22-28 sequence and amino acid 71-106 region. The protein has retinol dehydrogenase (RDH) 
activity, with enzymatic activity dependent on lipid droplet targeting and cofactor binding site. The exon 6 deletion, 
G insertion, and naturally occurring P260S mutation all confer loss of enzymatic activity. Conclusion: We demon-
strate the association of variants in HSD17B13 with specific features of NAFLD histology and identify the enzyme 
as a lipid droplet–associated RDH; our data suggest that HSD17B13 plays a role in NAFLD through its enzymatic 
activity. (Hepatology 2019;69:1504-1519).
The rise of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohep-atitis (NASH) has sparked considerable 
interest in pathogenic mechanisms of the disease. 
Racial and ethnic variability and a known herita-
ble component(1,2) hinted at a genetic contribution. 
Genome-wide association studies (GWAS) identified 
loci associated with NAFLD, most predominantly 
rs738409, a single-nucleotide polymorphism (SNP) 
in the patatin-like phospholipase domain-contain-
ing protein 3 (PNPLA3) gene.(3-5) Subsequently, we 
and others(6-8) demonstrated that rs738409 is strongly 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; GFP, green 
fluorescent protein; GWAS, genome-wide association study; HSD17B13, 17-beta hydroxysteroid dehydrogenase 13; indel, insertion/deletion; 
LD, linkage disequilibrium; MGI, Michigan Genomics Initiative; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; 
NASH CRN, NASH Clinical Research Network; OR, odds ratio; PNPLA3, patatin-like phospholipase domain-containing protein 3; RA, 
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associated with histological features and severity of 
NAFLD. Although the association is highly signif-
icant statistically, the effect size with regard to liver 
fat accumulation(9) is quite weak. Similarly, the major 
allele of the transmembrane 6 superfamily mem-
ber 2 (TM6SF2) SNP rs58542926 is associated with 
decreased liver fat(10) but, conversely, with higher 
serum lipid levels and increased risk of atherosclero-
sis and cardiovascular disease.(11) In vivo and in vitro 
studies provided evidence that TM6SF2 regulates 
very low-density lipoprotein secretion and acts as a 
determinant of liver damage or cardiovascular disease 
under metabolic stress.(10-14) Of other genes associated 
with NAFLD by GWAS, only a few (such as mem-
brane-bound O-acyltransferase domain containing 7 
[MBOAT7](15-17)) were studied in large histologically 
characterized NAFLD cohorts, and in even fewer has 
their mechanism been elucidated.
A recent large-scale GWAS identified loci associ-
ated with plasma liver enzyme levels.(18) In unselected 
population surveys, elevated transaminases occur con-
comitantly with metabolic syndrome risk factors(19,20) 
and are presumed to reflect hepatic fat accumula-
tion and related injury. However, a direct association 
between these SNPs and NAFLD has not yet been 
shown. We hypothesized that plasma transaminase 
activity in the GWAS reflected the presence of fatty 
liver and associated injury and that genetic associa-
tions with transaminases could identify genes involved 
in NAFLD pathogenesis. Our goals were to establish 
which of these described SNPs is associated with his-
tological features of NAFLD, identify the genes asso-
ciated with these SNPs, and elucidate the mechanism 
by which these genes affect NAFLD.
In this work we demonstrate that SNPs in or near 
17-beta hydroxysteroid dehydrogenase 13 (HSD17B13) 
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are associated with histological features of NAFLD, 
identify HSD17B13 as a retinol dehydrogenase (RDH), 
and characterize the impact of genetic variants on its 
enzymatic activity. Our study provides a link between 
genetic variants, retinoid metabolism, and NAFLD 
pathogenesis and identifies HSD17B13 as a potentially 
druggable target in NAFLD.
Patients and Methods
StUDy DeSIgN
We initially genotyped in a cohort of subjects 
with biopsy-proven NAFLD 38 SNPs described by 
Chambers et al.(18) to identify loci associated with histo-
logical features. After identifying a locus of interest, we 
genotyped additional SNPs in the candidate gene locus 
in the same cohort and confirmed associations in addi-
tional cohorts. Finally, we performed functional analyses 
to characterize the gene product and identify the func-
tional impact of gene variants (Supporting Fig. S1).
StUDy popUlatIoNS
The NAFLD cohort has been described in detail.(6) 
Briefly, we included patients from the NASH Clinical 
Research Network (NASH CRN) observational data-
base(21) and PIVENS(22) studies, as well as patients with 
biopsy-proven NAFLD seen at the National Institutes 
of Health Clinical Center. Analysis was limited to 
Caucasians aged ≥18 years at the time of liver biopsy. All 
subjects had histological evidence of NAFLD or NASH 
on liver biopsy. Liver histology was scored semiquantita-
tively using the NASH CRN scoring system.(23)
Confirmatory analyses were performed in a cohort 
of patients with chronic hepatitis C and available liver 
histology and in two population-based cohorts—the 
Michigan Genomics Initiative (MGI) and the UK 
Biobank.
HepatIC geNe eXpReSSIoN
Deidentified normal and NASH human liver 
samples were obtained from the Liver Tissue Cell 
Distribution System and from clinical trials at the 
National Institutes of Health Clinical Center. Gene 
expression was quantified by real-time quantitative 
PCR.
INtRaCellUlaR loCalIZatIoN
Cells were stained with primary antibodies against 
organelle markers, LipidTox Red (Life Technologies, 
Carlsbad, CA) for lipid droplets, and Hoechst 33342 
for nuclei. Staining was visualized using a confocal 
microscope.
RDH aCtIVIty
RDH activity was tested in a cell-based assay as 
described.(24) Briefly, HEK293 cells were transfected 
with protein expression vectors and treated with 
all-trans-retinol for 8 hours, followed by retinaldehyde 
and retinoic acid (RA) quantification by high-pressure 
liquid chromatography (HPLC) and protein quantifi-
cation by western blot.
StatIStICal aNalySIS
Associations between genotypes and histology 
were determined by a two-step method. Univariate 
analysis was performed using the Jonkheere-Terpstra 
test for ordered differences. SNPs with a univariate 
significance level <0.1 were selected for multivariate 
ordinal regression, with age, body mass index (BMI), 
gender, and type 2 diabetes as covariates. We used the 
Benjamini-Hochberg(25) false discovery rate to cor-
rect for multiple comparisons, using the calculator by 
Pike,(26) with q < 0.05 considered significant. P values 
are reported from the multivariate ordinal regression. 
Odds ratios (ORs) of associations with histology were 
calculated using binary logistic regression. An additive 
inheritance model was used. The Student t test was 
used for two-group differences, and one-way analy-
sis of variance followed by Dunnett’s multiple com-
parison test were used for more than two groups in 
the in vitro enzymatic assays. All significance testing 
was two-sided. Statistical analyses were performed 
using SPSS Statistics V.19 (IBM) and Prism V.7 
(GraphPad).
etHICS
Human subject data were obtained from studies 
conducted according to the Declaration of Helsinki 
principles that were reviewed by institutional review 
boards. All subjects gave written informed consent 
prior to inclusion.
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Additional details can be found in the Supporting 
Information.
Results
We obtained DNA from 768 adult Caucasians with 
biopsy-proven NAFLD (mean age, 49; mean BMI, 
34.6 kg/m2; 28.5% diabetic). Histologically, 59.5% 
had NASH and 12.1% had cirrhosis (Supporting 
Table S1). We genotyped in these subjects 38 SNPs 
described by Chambers et al.(18) (Supporting Table 
S2). The associations between SNPs and histological 
features of NAFLD are detailed in Supporting Table 
S3. Multivariate ordinal logistic regression adjusting 
for age, gender, diabetes, and BMI found nine SNPs 
to be significantly associated with steatosis grade, four 
SNPs associated with degree of ballooning degener-
ation, and two SNPs associated with Mallory-Denk 
bodies. No SNP was associated with severity of 
inflammation or fibrosis. Associations were indepen-
dent of the PNPLA3 rs738409 genotype (Supporting 
Table S3). Of the SNPs associated with NAFLD his-
tology, only rs6834314 was also associated with serum 
transaminases in patients with NAFLD (Supporting 
Table S4) and thus was the focus of subsequent study.
rs6834314 IS aSSoCIateD WItH 
NaFlD HIStology
rs6834314 is located on chromosome 4, 11 kb 
downstream of the HSD17B13 gene. Each copy of 
the minor G allele increased the risk of having liver 
fat content ≥33% (OR, 1.32; confidence interval [CI], 
1.02-1.70, Fig. 1A; Supporting Fig. S2A). The mean 
steatosis grade in subjects with rs6834314G/G gen-
otype was 0.2 units higher than in those with A/A 
(1.88 ± 0.87 versus 1.68 ± 0.89), an effect similar to 
the impact of the PNPLA3 rs738409 in the same 
subjects (0.21 units; 1.59 ± 0.84 for rs738409C/C 
versus 1.80 ± 0.89 for G/G).(6) In contrast to its asso-
ciation with increased liver fat, the minor G allele was 
significantly associated with lower risks for inflam-
mation (OR, 0.77 for total inflammatory score ≥3, 
CI 0.60-0.99), significant ballooning (OR, 0.67 for 
ballooning score >1, CI 0.51-0.87), and the presence 
of Mallory-Denk bodies (OR, 0.68; CI, 0.51-0.91) 
and showed a nonsignificant trend for reduced 
fibrosis (OR, 0.79; CI, 0.60-1.05) on binary logistic 
regression. The associations with inflammation, bal-
looning, and Mallory-Denk bodies were independent 
of the association with steatosis and, in fact, were 
stronger when steatosis grade was included in the 
regression model (Supporting Table S5). The minor 
allele of rs6834314 was also associated with lower 
serum transaminases and gamma-glutamyltrans-
ferase (Fig. 1B). NAFLD has been associated with 
genetic variants in PNPLA3 (rs738409), TM6SF2 
(rs58542926), MBOAT7 (rs626283), and glucoki-
nase regulator (rs1260326). After adjusting for these 
variants, rs6834314 remained significantly associated 
with steatosis (P = 0.013), ballooning (P = 0.031), and 
Mallory-Denk bodies (P = 0.030) and trended for 
association with inflammation (P = 0.067; Supporting 
Table S6). rs6834314 genotype did not differ between 
patients with NASH and those with steatosis only.
To validate the association of rs6834314 with ste-
atosis, we genotyped it in an independent sample of 
317 Caucasian patients with chronic hepatitis C and 
available liver histology (Supporting Table S7). Liver 
fat was present in 179 (57.2%) subjects. As with 
the NAFLD cohort, rs6834314 genotype was sig-
nificantly associated with the degree of steatosis in 
univariate (P = 0.032, Jonkheere-Terpstra test) and 
multivariate (P = 0.028, ordinal regression adjusted 
for BMI, age, and gender) analyses. Each copy of 
the minor G allele was significantly associated with 
the presence of liver fat (OR, 1.67; CI, 1.11-2.51; 
P = 0.015; Fig. 1C; Supporting Fig. S2B). As expected, 
rs6834314 genotype was not associated with hepati-
tis C virus–driven inflammation or fibrosis.
As further confirmation, we determined the associa-
tion of rs6834314 with liver enzymes and diagnoses in 
the MGI cohort (Supporting Table S8). rs6834314-G 
was associated with lower alanine aminotransferase 
(ALT) (P = 3.3 × 10–4) and aspartate aminotrans-
ferase (AST) (P = 5.1 × 10–5) and with a lower risk 
of cirrhosis diagnosis (OR, 0.79; P = 7.5 × 10–4; 
Supporting Fig. S2C). The MGI cohort is population- 
based, and histological data are not available for 
detailed analyses.
otHeR VaRIaNtS IN HSD17B13 
aRe aSSoCIateD WItH NaFlD
rs6834314 is downstream of HSD17B13 and in high 
linkage disequilibrium (LD) with multiple adjacent 
SNPs, overlapping parts of the HSD17B13 gene. To 
Ma et al. Hepatology, april 2019
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FIg. 1. HSD17B13-related SNPs are associated with liver disease. Association of rs6834314 genotype with (A) liver histology scores 
and (B) blood levels of liver enzymes in subjects with NAFLD (AA, n = 485; GA, n = 226; GG, n = 41). (C) Association of rs6834314 
genotype with liver histology scores in subjects with chronic hepatitis C (AA, n = 165; GA, n = 125; GG, n = 23). (D) Association of 
rs72613567 genotype with liver histology scores in subjects with NAFLD. (–/–, n = 503; –/A, n = 220; A/A, n = 35). (E) Association 
of rs62305723 genotype with liver histology scores in subjects with NAFLD (GG, n = 615; GA/AA, n = 76). Mean ± SEM. P values 
for histology from multivariate ordinal regression adjusted for age, gender, and BMI. P values for enzymes from linear regression 
of log-transformed enzyme activity, adjusted for age, gender, and BMI. Abbreviations: Alk. Phos., alkaline phosphatase; GGT, 
gamma-glutamyltransferase.
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determine whether the associations of rs6834314 reflect 
a biological effect of HSD17B13, we selectively geno-
typed additional variants in the gene region, including 
two nonsynonymous coding SNPs, an insertion/deletion 
(indel) polymorphism in a splice site, and a frameshift 
coding SNP, as well as seven SNPs that capture most 
of the common variants in the gene region (Table 1). 
The tag SNP, rs6834314, is in strong LD (D′ = 0.995, 
r2 = 0.93) with the indel rs72613567, located immedi-
ately adjacent to the 3′ end of exon 6 (Supporting Fig. 
S3). As expected, this indel had a similar pattern of asso-
ciation with NAFLD histology and liver enzymes as 
rs6834314 (Fig. 1D). The minor allele, rs72613567-A, 
was associated with increased steatosis (OR, 1.36; CI, 
1.04-1.77) but with decreased inflammation (OR, 0.74; 
CI, 0.57-0.96) and trended toward decreased balloon-
ing (OR, 0.78; CI, 0.60-1.03), Mallory-Denk bodies 
(OR, 0.77; CI, 0.57-1.03), and fibrosis (OR, 0.77; CI, 
0.58-1.03; Supporting Fig. S4A).
rs72613567 was not genotyped in the MGI 
cohort but was genotyped in the UK Biobank cohort 
(Supporting Table S9). The minor allele A inser-
tion was significantly less common in the NAFLD 
cohort (19.1%) compared to the population-based 
UK Biobank (27.9%, P < 0.001) and was associated 
with a reduction in the risk of fibrosis and cirrho-
sis (OR, 0.83; P = 9 × 10–4; Supporting Fig. S4B). 
rs72613567-A was also associated with lower risk of 
diagnoses of liver disease (OR, 0.93; P = 8 × 10–4), 
other inflammatory liver diseases (a diagnostic code 
that includes NASH; OR, 0.82; P = 0.0012), and alco-
holic liver disease (OR, 0.87; P = 0.015). Histological 
data or liver enzymes are not available for this cohort.
Another SNP, the nonsynonymous coding 
rs62305723G>A in exon 6, encodes a P260S substi-
tution and is not in LD with rs6834314 (r2 = 0.02). 
The rs62305723 minor A allele is significantly asso-
ciated with decreased inflammation (OR, 0.46; CI, 
0.28-0.74), ballooning (OR, 0.48; CI, 0.30-0.76), and 
Mallory-Denk bodies (OR, 0.51; CI, 0.28-0.91) but, 
in contrast to rs72613567/rs6834314, is not associ-
ated with steatosis (Fig. 1E; Supporting Fig. S5A). 
The minor A allele was associated with a lower risk 
of NASH compared to steatosis (OR, 0.39; CI, 
0.23-0.68; P = 0.001). In the UK Biobank cohort, 
rs62305723 was not associated with liver-related diag-
noses. Interestingly, the minor A allele was associated 
with a diagnosis of blindness or low vision (OR, 1.3; 
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Conditional analysis found rs62305723 and 
rs72613567 to associate with NAFLD histology 
independently of each other (Supporting Table S10), 
suggesting that both are causal variants. Including 
PNPLA3 rs738409 in the model did not impact sig-
nificance (Supporting Table S10), and the association 
of HSD17B13 SNPs with histology and ALT was 
seen for all rs738409 genotypes (Supporting Fig. S6). 
We found no significant interaction between rs738409 
and HSD17B13 SNPs, although our study was not 
powered to detect such an effect. Two additional 
noncoding SNPs (rs6531975, rs10022237), neither in 
LD with rs6834314, were associated with histologi-
cal features; and rs10022237 was also associated with 
ALT. Detailed mapping supports a functional role for 
HSD17B13 in the pathogenesis of NAFLD.
HepatIC HSD17B13 eXpReSSIoN IS 
eleVateD IN NaSH patIeNtS
To determine whether HSD17B13 is expressed dif-
ferentially in NAFLD, we quantified its expression in 
human NASH (n = 43) or normal (n = 14) liver sam-
ples. Hepatic expression of HSD17B13 was 5.9-fold 
higher in NASH patients compared with controls 
(P = 0.003; Fig. 2A).
In the GTEx database, rs6834314 genotype did 
not affect hepatic HSD17B13 expression (Supporting 
Fig. S7A; P = 0.6) and neither did rs72613567 and 
rs62305723 (data not shown). We confirmed this in 
a pooled analysis of our liver tissue samples (Fig. 2B). 
Because HSD17B13 expression is up-regulated in 
NAFLD, we examined whether rs6834314 modulates 
gene expression only in these subjects but found no 
significant impact of genotype on hepatic HSD17B13 
expression in either NASH (Supporting Fig. S7B) or 
normal (Supporting Fig. S7C) liver, although nearly 
all high-expression samples had A/A genotype. To 
confirm that rs6834314 does not affect HSD17B13 
expression in hepatocytes, as liver tissue samples 
contain other cell types, we quantified HSD17B13 
mRNA in primary human hepatocytes from 22 
donors and genotyped them for rs6834314. No donor 
was homozygous for the minor G allele, and there was 
no difference in HSD17B13 expression between A/A 
and A/G genotypes (Supporting Fig. S7D). Thus, 
hepatic HSD17B13 expression is up-regulated in 
NAFLD, but the association between rs6834314 gen-
otype and NAFLD phenotype is not due to changes 
in expression levels and more likely reflects a change 
in protein function.
HSD17B13 loCalIZeS to lIpID 
DRopletS
To better understand the function of HSD17B13, 
we determined its subcellular localization by trans-
fecting HSD17B13–green fluorescent protein (GFP) 
into HepG2 cells and staining for cellular organelle 
markers. HSD17B13-GFP colocalizes with the lipid 
FIg. 2. Hepatic expression of HSD17B13. (A) Expression levels 
of HSD17B13 by real-time quantitative PCR in liver samples 
from healthy controls (n = 14) and NASH patients (n = 43). 
(B) Expression levels of HSD17B13 by real-time quantitative 
PCR according to rs6834314 genotype in liver samples from 
control and NASH patients (A/A, n = 45; A/G or G/G, n = 12). 
rs6834314A/G and G/G were pooled together due to lower 
frequency. Lines denote median and interquartile range and are 
normalized to controls. The Mann-Whitney test was used for 
significance testing.
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droplets (Fig. 3A) and is detected on the surface of 
purified droplets from transfected cells (Fig. 3B) but 
does not colocalize with other organelles (Supporting 
Fig. S8A).
There are two described transcript variants for the 
human HSD17B13 gene, formed by alternative splicing: 
variant A contains all seven exons, while variant B 
is missing exon 2 (Supporting Fig. S3), resulting in 
deletion of amino acids 71-106 (Fig. 3C). Transfected 
HSD17B13(B)-GFP localized to the cytoplasm but 
not to lipid droplets (Fig. 3C,D). By site-directed 
mutagenesis, we identified the N-terminal amino acids 
FIg. 3. HSD17B13 localizes with lipid droplets. (A) HepG2 cells were transfected with HSD17B13(A)-GFP and stained for the 
lipid droplet marker protein ADRP (perilipin-2). (B) Lipid droplets were isolated from HSD17B13(A)-GFP-transfected cells and 
stained with the lipid droplet–specific dye LipidTox. (C) Mutations were generated and tested for cellular localization with LipidTox, 
which was used to stain lipid droplets. (D) HSD17B13(A)-GFP and HSD17B13(B)-Flag were cotransfected into HEK293 cells. 
Immunofluorescence staining was used to visualize HSD17B13(B)-Flag. Nuclei were counterstained with Hoechst 33342. One 
representative image from repeated experiments is shown. Bars, 10 μm.
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22-28 of HSD17B13 as essential for lipid droplet 
targeting (Fig. 3C). This seven–amino acid sequence 
is conserved within adipose differentiation–related 
protein (ADRP) and tail-interacting protein 47 kDa 
(perilipin-3), which are also lipid droplet– associated 
proteins(27) (Supporting Fig. S8B), and appears to be 
crucial for protein stability as its deletion results in low 
protein expression.
HSD17B13 DoeS Not aFFeCt 
HepatoCyte lIpID CoNteNt
To assess the functional role of HSD17B13 in 
the liver, we investigated whether its expression 
level affects fat content of HepG2 cells incubated 
with a high concentration of fatty acids. Expression 
of HSD17B13 protein was dose-dependently 
induced by doxycycline using the Tet-on inducible 
expression system (Supporting Fig. S9A) with no 
effect on lipid content (Supporting Fig. S9B,C). 
Similarly, stable HSD17B13 overexpression or 
knockout in HepG2 cells did not affect their lipid 
content (Supporting Fig. S9D,E), suggesting that 
HSD17B13 does not regulate hepatocyte lipid con-
tent in a direct manner.
HSD17B13 HaS RDH aCtIVIty  
IN VITRO
HSD17B13 is a member of the 17β hydroxys-
teroid dehydrogenase (HSD) family, 14 structur-
ally related enzymes implicated in steroid and fatty 
acid metabolism(28); the substrate of HSD17B13 
is currently unknown. Given the association of 
HSD17B13 with NAFLD, we hypothesized that its 
functional role is due to its enzymatic activity and 
that SNPs modulate that activity. Beyond its simi-
larity to the 17β-HSD family, HSD17B13 is struc-
turally similar to other members of the short-chain 
dehydrogenase/reductase 16C family (SDR16C),(29) 
which are known to play a critical role in retinoid 
metabolism through their RDH enzymatic activity, 
catalyzing the oxidation of retinol to retinaldehyde, 
the rate-limiting step in all-trans-RA biosynthesis 
(Fig. 4A). Cells transfected with HSD17B13(A) 
(variant A) demonstrated RDH activity comparable 
to that of the positive control RDH10(30) (Fig. 4B-D). 
In contrast, HSD17B13(B) had no RDH activ-
ity (Fig. 4E-G). HSD17B13-∆22-28, which does 
not target lipid droplets, also lacked RDH activity, 
although its expression was markedly lower than that 
of variants A and B, possibly because of low protein 
stability (Supporting Fig. S10). Thus, HSD17B13 
demonstrates in vitro RDH activity that requires 
lipid droplet targeting for its stability and enzymatic 
function.
HSD17B13 contains the conserved TGXXXGXG 
NAD(P)(H) cofactor binding site(31) common to 
SDRs.(32) We generated a mutation within this motif 
(HSD17B13-G47/G49A), which resulted in loss of 
RDH activity (Fig. 4H-J), confirming the need for 
cofactor binding for enzymatic activity.
tHe IMpaCt oF geNetIC 
VaRIaNtS IN HSD17B13 oN 
eNZyMatIC aCtIVIty
The nonsynonymous coding SNP rs62305723G>A 
encodes a P260S substitution. P260 is highly con-
served in vertebrate HSD17B13 orthologs and in 
other SDR16C family members (Fig. 5A), even 
though it is outside the predicted catalytic or cofac-
tor binding sites, suggesting its importance for pro-
tein function. We generated and tested this mutant 
form for enzymatic activity. Although the mutant 
protein HSD17B13(A)-P260S retains lipid droplet 
localization (Fig. 5B) similarly to wild-type pro-
tein, it lacks RDH activity (Fig. 5C-E). Thus, the 
minor allele of rs62305723 is generating a loss-of-
function mutation that is associated with decreased 
hepatic inflammation and injury in patients with 
NAFLD.
The indel rs72613567 was associated with histolog-
ical and serological features of hepatic fat and injury 
(Table 1). The indel is located in the 5′ end of the 
intron between exons 6 and 7, with the minor allele 
(A insertion) modifying a conserved splice donor 
sequence (GTAAGT to GTaAAGT). To deter-
mine whether this SNP affects splicing, we amplified 
and sequenced the surrounding regions from DNA 
and RNA of 36 human liver samples. We identified 
two HSD17B13 splice variants—one with a single 
G-nucleotide insertion (G insertion) between exons 
6 and 7, causing a frameshift and premature stop 
codon, and another with exon 6 skipping (delta-6) 
(Fig. 6A). Both the delta-6 and the G-insertion vari-
ants retain localization to lipid droplets (Fig. 6B) but 
have no RDH activity (Fig. 6C) and were only found 
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in subjects with the minor rs72613567A allele (Fig. 
6D,E), who, as expected, also carried the rs6834314 
minor G allele (Supporting Fig. S11A,B). Delta-6 
was expressed simultaneously with exon 6– containing 
variants at a relatively fixed ratio (Supporting Fig. 
S11C,D).
FIg. 4. HSD17B13 is an RDH. (A) Oxidation of retinol to retinaldehyde by RDHs (asterisk) is the rate-limiting step of RA synthesis. 
HEK293 cells transfected with HSD17B13(A), empty vector, or RDH10 as positive control were treated with retinol (5 μM), and levels 
of synthesized retinal (B) and RA (C) were measured by HPLC. Transfection of HSD17B13(B) variant does not lead to increased 
retinaldehyde (E) or RA (F) synthesis. Cofactor binding site mutation protein HSD17B13(A)-G47/49A has no RDH activity (H,I) in 
HEK293 cells treated with 2 μM retinol. Anti-Flag western blot used to determine protein transfection efficiency in each experiment 
(D,G,J). Data are presented as mean ± SEM. Abbreviation: WB, western blot.
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Discussion
In otherwise normal subjects, elevated plasma liver 
enzymes are often considered a surrogate for the 
presence of liver fat but can also reflect other liver 
processes, derive from nonhepatic sources, or reflect 
variability in the genes for the enzymes themselves. 
Chambers et al.(18) found at the population level sev-
eral genetic variants that associate with liver enzyme 
levels. We aimed to identify which of these associa-
tions actually reflects fatty liver or injury by assess-
ing the association of the variants with histological 
features of NAFLD. We identified several SNPs that 
associated with NAFLD features and by focusing on 
one of them, rs6834314, identified HSD17B13 as a 
lipid droplet enzyme associated with the disease.
Other 17β-HSDs act as molecular switches, mod-
ulating the activation of steroid hormone receptors 
FIg. 5. The P260S mutation in HSD17B13 (rs62305723G>A) is associated with loss of RDH activity despite lipid droplet targeting. 
(A) The P260S substitution is located within a highly conserved region of HSD17B13 orthologs and human homologs. (B) In HepG2 
cells transfected with HSD17B13-P260S-GFP, the mutant protein, similar to the wild-type protein, can be detected in lipid droplets. 
Transfection of HEK293 cells with HSD17B13-P260S-Flag does not lead to increased retinaldehyde (C) or RA (D) synthesis in the 
presence of 2 μM retinol despite adequate transfection efficiency (E). Data are presented as mean ± SEM. Abbreviation: WB, western blot.
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in target tissues.(28) In vivo, some 17β-HSDs may 
have targets other than steroid hormones, such as 
prostaglandins, bile acids, and cholesterol; and some 
have been implicated in fatty acid metabolism.(33) 
Compared to other family members that are restricted 
to gonads or ubiquitously expressed, HSD17B13 is 
predominantly expressed in the liver, and the protein 
is targeted from the endoplasmic reticulum to lipid 
droplets by its N-terminal region.(27,31,34) We con-
firmed HSD17B13’s lipid droplet localization and 
identified a conserved seven–amino acid sequence 
(amino acids 22-28) that is crucial for lipid droplet 
targeting. Interestingly, a naturally occurring splice 
variant, HSD17B13(B), that lacks exon 2 is not tar-
geted to lipid droplets, despite the presence of amino 
acids 22-28. In overexpression experiments using 
equal amounts of plasmid, the Δ22-28 variant and 
HSD17B13(B) demonstrate lower protein levels than 
wild type, suggesting that proper targeting is crucial 
for protein stability and protection from degrada-
tion; a similar phenotype was described for TM6SF2 
variants.(10)
We found HSD17B13 to be highly expressed in 
NAFLD patients, consistent with a recent report.(34) 
However, its specific target and physiological func-
tion have not been defined, and neither has its role in 
NAFLD pathogenesis. We establish that HSD17B13 
has RDH activity and that its enzymatic activity 
depends on lipid droplet targeting and cofactor bind-
ing. HSD17B13 clearly has RDH activity in vitro, 
and this assay can be used to assess the impact of 
genetic variations on enzymatic function. Although in 
vivo the enzyme may have other substrates in addi-
tion to retinol, retinol is still a plausible in vivo sub-
strate. Retinoids are stored as retinyl esters in the lipid 
droplets of hepatic stellate cells that, when activated, 
play critical roles in hepatic fibrogenesis. There is sig-
nificant evidence that vitamin A metabolites (retinal-
dehyde and RA) and retinol binding protein (RBP4) 
are associated with the pathogenesis of hepatic steato-
sis, fibrosis, adipogenesis, and insulin resistance.(35-40) 
Enzymes involved in retinol metabolism are up- 
regulated in hepatic lipid droplets in NAFLD.(34) 
Furthermore, PNPLA3, strongly associated with 
NAFLD,(3) acts as a retinyl-palmitate lipase to control 
serum retinol and the RBP4 level in NAFLD patients 
and to modulate stellate cell fibrogenesis.(41-44) This 
supports the critical role retinoid metabolism plays in 
NAFLD progression. The association of the P260S 
substitution with a diagnosis of blindness or low vision 
further supports a role for HSD17B13 in retinoid 
metabolism. In addition, the putative substrate bind-
ing sites (L153/L156, K208, L199/E202), homodi-
mer interaction sites, and the P260 residue found in 
this study are all crucial for enzymatic activity and are 
conserved within RDH10, DHRS3, and HSD17B11 
but not with other 17β-HSDs (Supporting Fig. 
S12). In addition, a recent study in mice heterozy-
gous for Rdh10 knockout found increased steatosis 
on a high-fat diet despite only a modest decrease in 
hepatic RA.(45) This suggests unique substrate speci-
ficity and is consistent with retinoids being the sub-
strate for HSD17B13. Ongoing in vivo experiments 
are aimed at confirming these findings. Hepatic 
HSD17B13 expression appears limited to hepato-
cytes, with no detectable expression in quiescent or 
activated stellate cells (data not shown). Whether 
HSD17B13 acts directly on the hepatocyte through 
modulation of hepatocyte RA synthesis or indirectly 
through a paracrine or autocrine effect remains to be 
shown. Our data suggest that HSD17B13 is a hith-
erto undescribed hepatic RDH and that its effect on 
NAFLD pathogenesis relates to its enzymatic activity 
and possibly to its impact on retinoid homeostasis. 
Further characterization of the enzymatic activity of 
HSD17B13 in vitro and in vivo can help clarify its 
role. The increased levels of HSD17B13 in NAFLD 
patients may reflect a separate pathological process in 
the multifactorial pathogenesis of NAFLD.
The genetic association of variants in HSD17B13 
with features of NAFLD is complex, with different 
SNPs associated with different phenotypic patterns. 
We identified two different and independent SNPs 
that result in loss-of-function variants and reduc-
tion in NAFLD-associated injury and inflammation 
and are likely causal variants. The rs62305723 SNP 
FIg. 6. HSD17B13 delta 6 and G-insertion variants localize with lipid droplets, lose RDH activity, and are associated with rs72613567. 
(A) Schema of HSD17B13 variants A, delta 6, and G insertion. (B) In HepG2 cells transfected with HSD17B13-delta 6-Flag or 
HSD17B13-G insertion-Flag, the mutant proteins can be detected in lipid droplets stained by LipidTox. (C) Transfection of HEK293 
cells with HSD17B13-delta 6 or HSD17B13-G insertion does not lead to increased RA levels. The delta 6 (D) and G-insertion (E) 
variants are only detected in subjects who carry the rs72613567 minor A allele.
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encodes a P260S mutation that abolishes the RDH 
activity in vitro. Conservation of P260 among verte-
brates in the HSD17B13 gene and in the SDR16C 
family indicates that this site is essential for protein 
function. A second SNP, rs72613567, generates two 
simultaneously expressed splice variants that are also 
devoid of enzymatic function and associated with 
decreased injury. This SNP is in high LD with the tag 
SNP, rs6834314, and likely explains the associations 
found with it, as well as the association with ALT 
reported by Chambers et al.(18) and Xu et al.,(46) espe-
cially because we demonstrate that rs6834314 is not 
an expression quantitative trait locus. Association with 
fibrosis stage, the major determinant of prognosis in 
NASH, was weaker; but rs6834314 and rs72613567 
are associated with cirrhosis in the MGI and UK 
Biobank cohorts, respectively, consistent with their 
impact on liver injury. Interestingly, both rs62305723 
and rs72613567 are located in or near exon 6 of the 
gene, away from the conserved catalytic and cofactor 
binding motifs of the 17β-HSD family.(28) Overall, 
our data support a role for HSD17B13 in mediat-
ing NAFLD-associated injury through its enzymatic 
activity.
Some variants in HSD17B13 were associated with 
histological degree of steatosis, including rs6834314, its 
associated splice SNP rs72613567, and other indepen-
dent SNPs. The association of rs6834314 with steato-
sis was confirmed in an independent cohort of patients 
with chronic hepatitis C. The alleles that associate 
with increased hepatic fat are those that associate with 
decreased injury, and the association with injury was 
independent of the association with steatosis. However, 
the loss-of-function P260S variant is not associated 
with steatosis. This suggests that the association with 
hepatic fat may be unrelated to the enzymatic activity 
and could be driven by another mechanism. This is also 
supported by our in vitro data, where knocking out or 
overexpressing HSD17B13 in hepatoma cells does not 
affect their fat-storage capacity. Consistent with our 
data, Abul-Husn et al.(47) reported that HSD17B13 
overexpression does not change cellular lipid con-
tent. In contrast, Adam et al.(48) recently found that 
Hsd17b13 knockout mice showed hepatic steatosis 
only at an older age, indicating that HSD17B13 might 
affect hepatic fat metabolism in vivo; the underlying 
mechanism is yet to be explored.
In a proteomic analysis of hepatic lipid drop-
lets, Su et al.(34) recently identified up-regulation of 
HSD17B13 in subjects with NAFLD, consistent with 
our results. They demonstrated an increase in lipid 
droplet size in cells overexpressing HSD17B13 tagged 
with GFP; we obtained similar results but were 
not able to replicate them when transfecting with 
HSD17B13 with a smaller tag (Flag epitope), suggest-
ing that the large GFP tag on lipid droplet–associated 
HSD17B13 causes nonspecific lipid aggregation (data 
not shown). HSD17B13 expression appears to be reg-
ulated by liver X receptor and sterol regulatory element 
binding protein 1c,(49) which can explain our finding 
of its up-regulation in patients with NASH and is 
consistent with a functional role in NAFLD patho-
genesis. Additional evidence supporting a role for 
HSD17B13 in lipid metabolism comes from a recent 
GWAS(50) in which rare variants in HSD17B13 were 
found to impact the effect of fenofibrate on plasma 
triglycerides and high-density lipoprotein.
Recently, Abul-Husn et al.(47) also reported that 
the splice-site SNP rs72613567 is associated with 
levels of ALT and AST and with the risk of chronic 
liver disease. Their findings, including the presence 
of loss-of-function splice variants associated with 
rs72613567, are consistent with ours and together 
highlight the role of HSD17B13 in liver injury. 
Whether the association with injury is specific to 
fatty liver disease is unclear. A major strength of our 
study compared to that of Abul-Husn et al.(47) is our 
focus on genetic associations with the separate spe-
cific histological components of NAFLD, allowing us 
to highlight the different impact on hepatic fat and 
injury. Our findings suggest that HSD17B13 affects 
injury and inflammation differently in NAFLD 
compared to viral hepatitis and that the association 
with steatosis may be due to a different mechanism. 
Furthermore, beyond the data on the impact of trun-
cated or unstable forms generated by the splicing 
SNP, also demonstrated by Abul-Husn et al.,(47) we 
describe a single–amino acid mutation of HSD17B13 
that confers loss of enzymatic activity despite stable 
protein expression and proper cellular localization and 
associate this mutation with histological severity of 
NAFLD. This confirms the link between enzymatic 
function and phenotype.
In conclusion, we confirmed that the association 
of rs6834314 with ALT reflects its association with 
NAFLD and that HSD17B13 represents the affected 
gene of interest. Our data establish HSD17B13 as a 
lipid droplet–associated protein and point to its RDH 
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activity as a key aspect of function, with a potential 
pathogenic link to NAFLD. Genetic variations in 
HSD17B13 have complex consequences that vary 
by type and locus, and further investigation into the 
genotype– phenotype association is warranted.
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